Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world

References

• McDanel J, Schweizer M, Crabb V, et al. Incidence of Extended-Spectrum β-Lactamase (ESBL)-producing escherichia coli and klebsiella infections in the United States: a systematic literature review. Infect Control Hosp Epidemiol. 2017;38:1209–1215.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–327.
   PubMed Web of Science ®Google Scholar
• Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–166.
   PubMed Web of Science ®Google Scholar
• CDC. The biggest antibiotic-resistant threats in the U.S. [Internet]. Centers for Disease Control and Prevention; 2019. [cited 2019 May 29]. Available from: https://www.cdc.gov/drugresistance/biggest_threats.html
   Google Scholar
• McLaughlin M, Advincula MR, Malczynski M, et al. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother. 2013;57:5131.
   PubMed Web of Science ®Google Scholar
• Chang H-J, Hsu P-C, Yang -C-C, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: A matched case–control study. J Microbiol Immunol Infect. 2011;44:125–130.
   PubMedGoogle Scholar
• Harris PNA, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15:475–485.
   PubMed Web of Science ®Google Scholar
• Bush K, Macalintal C, Rasmussen BA, et al. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother. 1993;37:851–858.
   PubMed Web of Science ®Google Scholar
• Marchaim D, Sunkara B, Lephart PR, et al. Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol. 2012;33:853–855.
   PubMed Web of Science ®Google Scholar
• Burgess DS, Hall RG. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2004;49:41–46.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Navarro MD, Retamar P, et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54:167–174.
   PubMed Web of Science ®Google Scholar
• Retamar P, López-Cerero L, Muniain MA, et al. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2013;57:3402–3404.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–1325.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of β-Lactam/β-Lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60:4159–4169.
   PubMed Web of Science ®Google Scholar
• Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320:984–994.
   PubMed Web of Science ®Google Scholar
• Henderson A, Tambyah P, Lye D, et al. Association with 30-day mortality and MIC in patients treated with piperacillin/tazobactam for Escherichia coli and Klebsiella pneumoniae bloodstream infections that are non-susceptible to ceftriaxone from patients enrolled in the MERINO trial. Amsterdam (Netherlands): ECCMID; 2019.
   Google Scholar
• Felton TW, Hope WW, Lomaestro BM, et al. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother. 2012;56:4087.
   PubMed Web of Science ®Google Scholar
• VanScoy BD, Rubino CM, McCauley J, et al. Determination of the tazobactam exposure required for piperacillin efficacy using a one-comparement in vitro infection model. Boston (MD): ASM Microbe; 2016.
   Google Scholar
• Zosyn [Package Insert]. Philadelphia (PA): Pfizer; 2012.
   Google Scholar
• Muller A, Bhagwat S, Patel M, et al. Development of a population model of tazobactam including high doses. Boston (MA): ASM Microbe; 2016.
   Google Scholar
• Caro L, Larson K, Nicolau D, et al. Pharmacokinetics/pharmacodynamics and safety of 3 g ceftolozane/tazobactam in critically ill adult patients. San Diego (CA): ID Week; 2017.
   Google Scholar
• Sutherland CA, Crandon JL, Nicolau DP. Defining extended spectrum β-Lactamases: implications of minimum inhibitory concentration-based screening versus clavulanate confirmation testing. Infect Dis Ther. 2015;4:513–518.
   Web of Science ®Google Scholar
• Vanscoy B, Mendes RE, McCauley J, et al. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane. Antimicrob Agents Chemother. 2013;57:5924–5930.
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. [Internet]. Version 9.0; 2019. [cited 2019 June 30]. Available from: http://www.eucast.org
   Google Scholar
• Popejoy MW, Paterson DL, Cloutier D, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother. 2017;72:268–272.
   PubMed Web of Science ®Google Scholar
• Kollef M, Novacek M, Kivistik U, et al. ASPECT-NP: a randomized, double-blind, phase 3 trial comparing efficacy and safety of ceftolozane/tazobactam vs meropenem in patients with ventilated nosocomial pneumonia. Amsterdam (Netherlands): ECCMID; 2019.
   Google Scholar